[{"orgOrder":0,"company":"AdjuTec Pharma","sponsor":"Venus Remedies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"APC-148","moa":"||MBL","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AdjuTec Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AdjuTec Pharma \/ Venus Remedies","highestDevelopmentStatusID":"4","companyTruncated":"AdjuTec Pharma \/ Venus Remedies"}]

Find Clinical Drug Pipeline Developments & Deals by AdjuTec Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Venus Remedies will test APC-148, a selective inhibitor targeting bacterial MBL enzymes, in combination with various antibiotics against multidrug-resistant bacterial strains.

                          Product Name : APC-148

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 26, 2025

                          Lead Product(s) : APC-148,Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Venus Remedies

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank